Skip to main content

Security report for biogenitalia.it

Biogen Italia S.r.l. · Healthcare · Italy

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Italia S.r.l. is a large, well-established biotechnology company operating in Italy as a subsidiary of the global Biogen Inc. The company specializes in innovative therapies for neurological, immunological, and rare diseases, with a strong focus on multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The website reflects a professional corporate presence with clear branding, comprehensive content, and a user-friendly design targeting healthcare professionals and patients in Italy. Technically, the site is built on Adobe Experience Manager, uses modern analytics and consent management tools, and is hosted likely on AWS infrastructure. Security posture is strong with HTTPS, HttpOnly cookies, and GDPR-compliant cookie consent mechanisms, although no explicit security policy or incident response contacts are published. Overall, the site is trustworthy, compliant, and well-maintained, supporting Biogen's market position as a leader in biotechnology.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogenitalia.it

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention biogenitalia.it, from OffSeq Breach.

No leaked records found

Breach holds no records for biogenitalia.it right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Italia operates as a subsidiary of Biogen Inc., leveraging global research and development capabilities to serve the Italian market. The company’s business model centers on pharmaceutical innovation and commercialization of therapies for complex diseases. Its market positioning is strong due to pioneering treatments and a diversified portfolio. The website indicates a mature digital presence with integrated analytics and consent management, reflecting compliance with European privacy regulations. The company maintains a broad partnership ecosystem, evident from multiple localized Biogen domains worldwide. Growth indicators include active recruitment and social responsibility initiatives. The absence of direct contact emails or phone numbers on the homepage suggests a controlled communication channel, likely via contact forms or corporate contacts.

Security posture

The website demonstrates a solid security posture with enforced HTTPS, use of HttpOnly cookies, and cookie consent management via Cookiebot. Google Analytics is configured with IP anonymization, enhancing privacy compliance. No security.txt or explicit vulnerability disclosure policies are found, which could improve transparency and incident response readiness. No exposed sensitive data or vulnerable libraries were detected in the HTML content. The site lacks a published security policy or dedicated incident response contact, which are recommended best practices. Overall, the security maturity is good but could be enhanced by publishing explicit security governance documents and establishing clear incident response channels.

Recommendations

  1. Publish a dedicated security policy page outlining security governance and controls.
  2. Provide explicit incident response contact information, such as security@ or abuse@ email addresses.
  3. Implement and publish a security.txt file to facilitate vulnerability disclosures.
  4. Enhance website accessibility features to improve compliance and user experience.
  5. Regularly audit and update third-party scripts and libraries to mitigate potential vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Italia S.r.l.
Description
Biogen è un’azienda globale leader nel settore delle biotecnologie e pioniera di numerose innovazioni medico-scientifiche nelle aree della neurologia, immunologia e malattie rare.
Key services
Therapies for Multiple Sclerosis, Treatment for Spinal Muscular Atrophy, Treatments for Alzheimer's disease, Research and development in biosimilars
Content quality
good
Branding
consistent

Technology

Stack
Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics, jQuery 3.6.4
Frameworks
Adobe Experience Manager (AEM)
Platforms
Web
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • Use of HttpOnly cookies
  • Cookie consent with blocking mode
  • IP anonymization in Google Analytics

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured
  2. Comprehensive cookie consent and privacy mechanisms implemented
  3. No exposed sensitive data or security vulnerabilities detected
  4. Strong presence of corporate branding and social media links
  5. No signs of malicious or suspicious activity
  6. Content is fully accessible without WAF or blocking mechanisms
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS platform, indicating a mature digital infrastructure. It uses modern JavaScript libraries including jQuery 3.6.4 and integrates Cookiebot for consent management and Google Tag Manager for analytics deployment. Hosting appears to be on AWS, inferred from load balancer cookies. Performance is moderate with asynchronous script loading and responsive design for mobile devices. SEO is supported by comprehensive meta tags and Open Graph data. Accessibility is basic but could be improved. No critical technical debt or deprecated technologies were observed. The site uses secure cookies and enforces HTTPS, contributing to a secure and reliable user experience.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogenitalia.it. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogenitalia.it.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.